

# Clustering of Blood Glucose Dynamics in Type 1 Diabetes

Szabó Ákos

*John von Neumann Faculty of Informatics  
Óbudai Egyetem  
Budapest, Hungary  
szabakos@stud.uni-obuda.hu*

Csepely Milán

*John von Neumann Faculty of Informatics  
Óbudai Egyetem  
Budapest, Hungary  
milan.csepely@stud.uni-obuda.hu*

Martines Gergő

*John von Neumann Faculty of Informatics  
Óbudai Egyetem  
Budapest, Hungary  
martinesgergo@stud.uni-obuda.hu*

Szász Dávid Máté

*John von Neumann Faculty of Informatics  
Óbudai Egyetem  
Budapest, Hungary  
szasz david@stud.uni-obuda.hu*

**Abstract**—This document presents the clustering analysis of Type 1 Diabetes and the associated metabolic simulators. We introduce the py-mGIPsim and DMMS.R systems and provide a comparative overview of their functionalities.

**Index Terms**—cukorbetegség, 1-es típus, szimulátor, metabolikus modell, DMMS.R, py-mGIPsim

## TYPE 1 DIABETES[1]

Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas. These beta cells make insulin, a hormone that allows blood sugar (glucose) to enter the body's cells and provide energy. When enough beta cells are destroyed, the pancreas produces little or no insulin, making it necessary to take insulin to survive.

Without sufficient insulin, glucose cannot move from the bloodstream into the cells, causing blood sugar levels to rise. This condition, called hyperglycemia, can lead to long-term damage to the heart, kidneys, eyes, nerves, and other organs if left untreated.

Type 1 diabetes is often diagnosed in children, teenagers, and young adults, but it can develop at any age. The exact cause of the disease is not fully understood, and researchers are still studying what triggers the immune system to attack the pancreas. Currently, there is no known way to prevent type 1 diabetes.

People with type 1 diabetes can live long and healthy lives by carefully managing their condition. A treatment plan, developed with a healthcare team, usually includes taking insulin, following a balanced diet, staying physically active, and monitoring blood glucose levels regularly. Having a strong support system from family, friends, and healthcare providers is also essential for maintaining health and achieving personal goals.

## TREATMENT OF TYPE 1 DIABETES[2]

Managing Type 1 diabetes (T1D) primarily revolves around insulin therapy, which replaces the insulin your body no longer produces. Since T1D is a self-managed condition, you'll make daily decisions about your insulin needs to keep your blood sugar levels in a target range.

Insulin comes in various forms, each with different speeds of onset and duration of action. You'll likely need a combination:

- **Basal Insulin (Long-Acting):** Provides a continuous, background level of insulin to manage glucose between meals and overnight.
- **Bolus Insulin (Mealtime and Correction):** Specific doses you take when you eat (to cover carbohydrates) and to correct elevated blood sugar levels.

You can administer insulin in several ways:

- **Multiple Daily Injections (MDI):** Involves drawing a dose from an insulin vial using a syringe for injection into the fatty tissue beneath the skin.
- **Insulin Pens:** Pre-filled devices used to inject specific doses into the fatty tissue.
- **Insulin Pumps:** A device that delivers insulin continuously through a small tube inserted under the skin, aiming to mimic the natural function of the pancreas. Doses can also be delivered on demand.

## FIRST SIMULATOR: PY-MGIPSIM

The mGIPsim (Metabolic Glucose-Insulin Physiology Simulator) is an open-source metabolic simulator that models the changes in blood glucose and insulin levels of 20 virtual Type 1 Diabetes (T1D) patients under various therapeutic, dietary, and physical activity conditions. The system's purpose is to provide a realistic simulation environment for research, education, and development purposes, where users can examine

the dynamics of glucose-insulin regulation using customizable parameters.

The simulator is written in Python and uses a vectorized, JIT (Just-In-Time) compiled computational model, which enables fast and efficient execution even with large amounts of simulation data. The system has a modular structure, making it easy to extend with new patient models, insulin dosing strategies, or control algorithms.

The software offers several user interfaces:

- Graphical User Interface (GUI) – A Streamlit-based web application that allows for interactive parameter setting and visualization.
- Interactive Command Line Mode (CMD) – A console user interface where the simulation can be configured step-by-step.
- Simple Command Line Interface (CLI) – A simulation that can be run from a single command line with predefined parameters.

mGIPsim supports various insulin therapy protocols, including:

- MDI (Multiple Daily Injections),
- SAP (Sensor-Augmented Pump Therapy),
- Hybrid Closed-Loop rendszer.

By varying parameters for meals, exercise, and insulin administration, the simulation can demonstrate the time-course of blood glucose levels over several days. The model also takes into account individual physiological differences, so each of the 20 virtual patients has a distinct metabolic dynamic.

The project is a valuable tool for research and development for testing insulin dosing algorithms, simulating diabetes management strategies, and teaching digital healthcare systems. For developers, the modular code structure and documented API interface allow for the integration of new models or the customization of the simulation logic.

## SECOND SIMULATOR: DMMS.R

The DMMS.R (Diabetes Mellitus Metabolic Simulator - Research) is a professional metabolic simulator developed for research purposes. The application is capable of modeling the physiological processes of Type 1 and Type 2 Diabetes, as well as prediabetes, in virtual patients. The simulator includes 55 virtual subjects, categorized into different patient groups: Type 1 children, adolescents, and adults; Type 2 adults; and prediabetic adults. Each subject has unique, predefined metabolic parameters. The simulator's primary goal is to provide preliminary and safe support for clinical trials.

The simulation is based on a compartmentalized glucose-insulin metabolic model that tracks the dynamics of hormones, blood glucose levels, and insulin at minute-level time resolution. The model accounts for meals, physical activity, insulin administration, pharmacological treatment, and circadian rhythm. The system supports insulin pharmacokinetics and pharmacodynamics, bioavailability, slow-release formulations, and the calculation of the amount of active insulin (Insulin-On-Board).

The DMMS.R has a modular structure, consisting of three main components:

- Virtual Patient Database: Contains the various metabolic characteristics.
- Mathematical Simulation Engine: Calculates the physiological processes.
- Graphical Interface: Used to configure the simulation.

The simulator allows for the configuration of various sensor, controller, and delivery elements:

- Ideal or noisy CGM and SMBG sensors (Continuous/Self-Monitoring of Blood Glucose).
- Meal, correction, and basal insulin controllers.
- Insulin pumps and injection delivery systems.

Pharmacological treatments, exercise programs, and meals can be prescribed for the patients within the program. Noise can also be applied during the simulation to model real-world measurement and administration uncertainties.

The simulation results are presented through:

- Detailed time-series graphs.
- CVGA (Control-Variability Grid Analysis).
- Individual and population-level statistical indicators.

The data can be exported in CSV and MATLAB formats.

The DMMS.R primarily serves research, development, and medical device validation purposes. It is suitable for the preliminary study and testing of insulin pumps, drug therapies, and digital diabetes management systems without the need for experimenting on real patients. The program is specifically designed for a clinical research environment.

## I. COMPARING THE TWO SIMULATORS

Aspect	py-mGIPsim	DMMS.R
Main purpose	Flexible simulation for research and development	Professional simulator designed for clinical research and validation
Modeled patients	20 virtual Type 1 diabetes patients	55 virtual patients: Type 1, Type 2, and prediabetes
Level of detail	Medium-high level physiological model	Highly detailed, clinically oriented compartment models
User interface	GUI, interactive CMD, simple CLI	Dedicated graphical interface
Therapy / control	MDI, SAP, Hybrid Closed-loop	Insulin pumps, injections, CGM/SGBM, medications
Noise and realism	Primarily deterministic modeling	Measurement and dosing noise
Outputs	Blood glucose time series, well-visualizable results	Detailed time series, statistical analyses
Extensibility	Highly extensible, developer-friendly	Structured, tied to clinical environments
Technology	Python, JIT-optimized execution	Mathematical engine focused on research

## RESULT ON BOTH SIMULATORS WITH THE SAME INPUTS

The objective of the experiment is to investigate how the insulin levels of 20 healthy adults change over the course of one day following three standardized meals. All participants

receive the same amount of carbohydrates for breakfast, lunch, and dinner, ensuring that differences between the measured insulin responses are attributable solely to individual physiological variations.

During the study, participants do not engage in exercise and are prohibited from consuming any snacks, treats, or supplementary foods. They receive only the three meals specified in the protocol:

- Breakfast at 7:00 AM: 60 grams of carbohydrates
- Lunch at 1:00 PM: 75 grams of carbohydrates
- Dinner at 7:00 PM: 60 grams of carbohydrates

The simulation is run for a duration of one day (24 hours).

In subsequent experimental phases, a separate analysis will be performed to determine how the addition of snacks and the incorporation of physical activity modify the insulin response.

## II. SIMULATION INPUTS AND OUTPUTS

### A. Inputs

The input data for the simulations consists of the pre-programmed datasets provided by the simulators, along with the basal and bolus insulin values calculated individually for each patient based on their specific physiological needs. These values are highly personalized and vary significantly from person to person, making any corrections or adjustments particularly challenging to compute. This individualized variability is one of the reasons why clustering such data presents considerable difficulties.




Figure 1. Graphical summary of input data showing variability among patients.

The figure above illustrates the basal insulin rates for all 20 patients over a 24-hour period. As can be observed in the graphs, there is no clear or direct correlation between body weight and the amount of insulin required by each individual. The insulin requirements are highly inconsistent across patients, though a general trend appears to emerge when analyzing different age groups. This indicates that age may play a more significant role than body weight in determining insulin needs.

The following figures below illustrate the correction boluses administered at breakfast, lunch, and dinner. Both sets of graphs demonstrate broadly similar trends; however, the differences between them reflect how each individual responds




Figure 2. Correction boluses at breakfast, lunch, and dinner across patients.

to bolus insulin. The second set of graphs is derived from the DMMS.R simulator, which includes data for children and adolescent patients. For our analysis, these younger age groups will not be simulated, and we will only compare ten patients from each simulator to ensure a fair comparison.




Figure 3. \*

py-mGIPsim: Correction boluses at breakfast, lunch, and dinner.




Figure 4. \*

DMMS.R: Correction boluses at breakfast, lunch, and dinner.

Figure 5. Comparison of correction boluses from the two simulators. The top figure shows py-mGIPsim data, while the bottom shows DMMS.R data, which also includes children and adolescent patients.

### B. Output

Having reviewed the input data and the graphical summaries for all 20 patients, we can now proceed to run the simulation. The first step is to examine the timeline of an individual patient, where the bolus insulin doses and carbohydrate intake events are explicitly labeled in relation to the full daily profile.

After implementing several helper functions to extract the relevant information from both simulator outputs, we are able to compute key glucose-related features for each patient. This

allows us to determine which individuals remained within the target glycemic range during the simulation period and which did not.




Figure 6. Daily insulin and carbohydrate profile for a representative patient. Time of Meals and Bolus Insulin doses are marked.

Patient	Avg	Min	Max	In	Below	Above
person_1	72.52	64.15	87.49	45.49	54.51	0.00
person_2	83.51	72.45	101.49	100.00	0.00	0.00
person_3	103.93	67.44	155.93	71.18	28.82	0.00
person_4	78.64	61.38	103.96	67.57	32.43	0.00
person_5	90.45	68.03	121.24	65.49	34.51	0.00
person_6	80.85	74.87	90.48	100.00	0.00	0.00
person_7	71.48	59.02	90.20	54.93	45.07	0.00
person_8	80.51	69.84	99.25	99.03	0.97	0.00
person_9	70.86	60.44	95.11	42.85	57.15	0.00
person_10	96.66	72.35	131.13	100.00	0.00	0.00
person_11	91.41	77.90	116.04	100.00	0.00	0.00
person_12	77.43	62.67	101.28	64.10	35.90	0.00
person_13	92.27	82.45	109.86	100.00	0.00	0.00
person_14	77.13	71.34	83.70	100.00	0.00	0.00
person_15	68.82	61.36	83.85	35.07	64.93	0.00
person_16	94.18	70.03	125.14	100.00	0.00	0.00
person_17	100.45	70.39	144.52	100.00	0.00	0.00
person_18	71.57	64.82	88.99	46.11	53.89	0.00
person_19	94.19	81.20	116.69	100.00	0.00	0.00
person_20	73.05	66.30	78.95	77.29	22.71	0.00

Table 1  
\*

Avg: Average glucose level (mg/dL), Min: Minimum glucose level (mg/dL), Max: Maximum glucose level (mg/dL), In: Percentage of time within target range (70-180 mg/dL), Below: Percentage of time below target range (<70 mg/dL), Above: Percentage of time above target range (>180 mg/dL).

The results show that all patients spent the majority of their time within—or below—the designated glucose range, and none exceeded the upper threshold during this simulation run. Notably, most of the time spent below the target range occurred during the early hours of the day. This behavior contrasts with the DMMS.R simulator, where patients frequently dropped below the lower limit even during daytime periods.

## SUMMARY

The goal of this project was to study and compare blood glucose dynamics in people with type 1 diabetes, focusing on how different metabolic simulators behave when the same




Figure 7. Glucose trajectories for py-mGIPsim.




Figure 8. Glucose trajectories for patients in DMMS.R. The dataset includes children and adolescent patients. This figure is presented for comparison with py-mGIPsim.

inputs are used. A one-day simulation with a standardized meal plan was applied, and insulin and glucose responses were analyzed for virtual patients.

The analysis of the input data showed that insulin needs vary greatly between individuals and do not have a clear relationship with body weight. Age appeared to have a stronger influence. This large variability is similar to what is seen in real clinical practice and makes clustering the data more challenging.

The simulation results showed that, in both simulators, patients spent most of their time within the target blood glucose range of 70–180 mg/dL. However, differences were observed between the two models. In the py-mGIPsim simulations, low blood glucose levels mainly occurred in the early morning, while in the DMMS.R simulations, low glucose values were more common during the daytime. These differences highlight how the structure of the model, the level of physiological detail, and the way uncertainty and noise are handled can strongly affect simulation results.

## PLANS FOR FUTURE WORK

The planned future work is to extend the simulations by adding snack intake and physical exercise, making the scenarios more realistic. In addition, clustering methods will be

applied to the simulation results in order to group patients based on their blood glucose dynamics and identify common patterns in behavior.

## REFERENCES

- [1] Understanding Type 1 Diabetes | ADA.  
URL: <https://diabetes.org/about-diabetes/type-1>
- [2] Management and treatment. Cleveland Clinic. URL:  
<https://my.clevelandclinic.org/health/diseases/21500-type-1-diabetes>